SCHEMBL25824324

SCHEMBL25824324

COc1ccc(OCCCC(=O)N2CCC(N)CC2)cc1C1CCC(=O)NC1=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 2/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
CRBN Q96SW2 3/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
PDE3B Q13370 9/20 0.41
PDE3A Q14432 9/20 0.41
DDB1 Q16531 2/20 0.40
P2RY12 Q9H244 2/20 0.39
ADAM17 P78536 1/20 0.39
MTNR1B P49286 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PDE2A O00408 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25824322 0.84 CRBN (0.41) ALDH1A1KMT2AHPGDMEN1LMNA
SCHEMBL25033939 0.83 CRBN (0.60) ALDH1A1KMT2AHPGDMEN1LMNA
SCHEMBL30475454 0.82 ALDH1A1 (0.42) ALDH1A1KMT2AHPGDMEN1LMNA
SCHEMBL25035194 0.82 ALDH1A1 (0.42) ALDH1A1KMT2AHPGDMEN1LMNA
SCHEMBL25029389 0.81 CRBN (0.53) ALDH1A1KMT2AHPGDMEN1LMNA
SCHEMBL25824646 0.81 ADAMTS5 (0.40) ALDH1A1KMT2ACRBNPDE3BPDE3A
SCHEMBL25033922 0.80 ALDH1A1 (0.42) ALDH1A1KMT2AHPGDMEN1LMNA
SCHEMBL30479035 0.74 CRBN (0.48) ALDH1A1HPGDCRBNNPC1RAB9A
SCHEMBL30984703 0.70 CRBN (0.48) LMNACRBNRAB9ADDB1TSHR
SCHEMBL25575940 0.69 CRBN (0.54) CRBNDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ALDH1A1 4008/4885KMT2A 1840/4885HPGD 3219/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 ALDH1A1 2752/4885KMT2A 1115/4885HPGD 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.